DK4328309T3 - Lipidsammensætning - Google Patents
LipidsammensætningInfo
- Publication number
- DK4328309T3 DK4328309T3 DK24150973.6T DK24150973T DK4328309T3 DK 4328309 T3 DK4328309 T3 DK 4328309T3 DK 24150973 T DK24150973 T DK 24150973T DK 4328309 T3 DK4328309 T3 DK 4328309T3
- Authority
- DK
- Denmark
- Prior art keywords
- lipid composition
- lipid
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/16—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019207118 | 2019-11-15 | ||
| EP20886910.7A EP4059505B1 (en) | 2019-11-15 | 2020-11-13 | Lipid composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK4328309T3 true DK4328309T3 (da) | 2025-08-18 |
Family
ID=75912395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK24150973.6T DK4328309T3 (da) | 2019-11-15 | 2020-11-13 | Lipidsammensætning |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220273817A1 (https=) |
| EP (2) | EP4059505B1 (https=) |
| JP (2) | JP7389134B2 (https=) |
| KR (4) | KR20250171478A (https=) |
| CN (2) | CN117417265B (https=) |
| CA (1) | CA3158293C (https=) |
| DK (1) | DK4328309T3 (https=) |
| ES (1) | ES3036322T3 (https=) |
| FI (1) | FI4328309T3 (https=) |
| PL (1) | PL4328309T3 (https=) |
| WO (1) | WO2021095876A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102591743B1 (ko) | 2018-06-08 | 2023-10-19 | 후지필름 가부시키가이샤 | 화합물 또는 그 염 및 지질 입자 |
| WO2020246581A1 (ja) | 2019-06-07 | 2020-12-10 | 富士フイルム株式会社 | 脂質組成物 |
| EP4059505B1 (en) * | 2019-11-15 | 2024-02-21 | FUJIFILM Corporation | Lipid composition |
| CN117279888A (zh) * | 2021-04-28 | 2023-12-22 | 富士胶片株式会社 | 化合物或其盐、脂质颗粒及药物组合物 |
| CN114149337B (zh) * | 2021-07-07 | 2022-04-29 | 天津键凯科技有限公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物 |
| CN120420422A (zh) * | 2022-01-30 | 2025-08-05 | 康希诺生物股份公司 | 一种用于核酸递送的新型可电离脂质及其lnp组合物和疫苗 |
| CN118891051A (zh) | 2022-03-15 | 2024-11-01 | 富士胶片株式会社 | 脂质组合物 |
| CN118984831A (zh) | 2022-03-15 | 2024-11-19 | 富士胶片株式会社 | 化合物及脂质组合物 |
| WO2023178425A1 (en) * | 2022-03-23 | 2023-09-28 | Nanovation Therapeutics Inc. | High sterol-containing lipid nanoparticles |
| WO2024014430A1 (ja) | 2022-07-11 | 2024-01-18 | 富士フイルム株式会社 | アミノ脂質又はその塩の製造中間体としての化合物、及びそれを用いたアミノ脂質化合物の製造方法 |
| AU2023316579A1 (en) | 2022-07-29 | 2025-02-13 | Fujifilm Corporation | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE |
| JP2025537180A (ja) * | 2022-11-03 | 2025-11-14 | シャンハイ サーコード バイオメッド カンパニー,リミティド | 脂質化合物、脂質ナノ粒子、及び医薬組成物 |
| WO2024158042A1 (ja) * | 2023-01-27 | 2024-08-02 | 富士フイルム株式会社 | 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア |
| AU2024234895A1 (en) | 2023-03-13 | 2025-09-18 | Fujifilm Corporation | Compound or salt thereof, lipid composition, pharmaceutical composition, and delivery carrier |
| WO2025070702A1 (ja) * | 2023-09-27 | 2025-04-03 | 富士フイルム株式会社 | 抗体の産生方法、および抗体の産生方法において使用するための脂質組成物 |
| WO2025143232A1 (ja) * | 2023-12-28 | 2025-07-03 | 富士フイルム株式会社 | 免疫細胞への核酸送達剤、および免疫細胞に核酸を送達する方法 |
| WO2025192731A1 (ja) * | 2024-03-15 | 2025-09-18 | 富士フイルム株式会社 | 化合物またはその塩、脂質組成物、医薬組成物および送達キャリア |
| WO2026004829A1 (ja) * | 2024-06-24 | 2026-01-02 | 富士フイルム株式会社 | 脂質ナノ粒子の製造方法 |
| WO2026004828A1 (ja) * | 2024-06-24 | 2026-01-02 | 富士フイルム株式会社 | 脂質ナノ粒子の製造方法 |
| CN120535478A (zh) * | 2025-01-23 | 2025-08-26 | 上海环码生物医药有限公司 | 脂质化合物、脂质纳米颗粒和药物组合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| JP5288254B2 (ja) | 2008-10-17 | 2013-09-11 | 株式会社ニコン | レンズ系 |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| JP2013245107A (ja) | 2012-05-29 | 2013-12-09 | Kuma Lift Gijutsu Kenkyusho:Kk | 椅子式階段昇降装置 |
| TW201534578A (zh) | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | 新穎脂質 |
| US10426737B2 (en) * | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| EP3083556B1 (en) | 2013-12-19 | 2019-12-25 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| HUE060907T2 (hu) * | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| JP6637988B2 (ja) | 2014-11-18 | 2020-01-29 | アークトゥルス セラピューティクス, インコーポレイテッド | Rna送達のためのイオン化可能カチオン性脂質 |
| CA3040337A1 (en) * | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| AU2017356699B2 (en) * | 2016-11-08 | 2021-11-11 | Ramot At Tel-Aviv University Ltd. | Cationic lipids for nucleic acid delivery and preparation thereof |
| KR102591743B1 (ko) * | 2018-06-08 | 2023-10-19 | 후지필름 가부시키가이샤 | 화합물 또는 그 염 및 지질 입자 |
| WO2020246581A1 (ja) * | 2019-06-07 | 2020-12-10 | 富士フイルム株式会社 | 脂質組成物 |
| EP4059505B1 (en) * | 2019-11-15 | 2024-02-21 | FUJIFILM Corporation | Lipid composition |
| JP7518909B2 (ja) * | 2020-09-14 | 2024-07-18 | 富士フイルム株式会社 | 脂質組成物 |
-
2020
- 2020-11-13 EP EP20886910.7A patent/EP4059505B1/en active Active
- 2020-11-13 KR KR1020257039932A patent/KR20250171478A/ko active Pending
- 2020-11-13 KR KR1020247016735A patent/KR20240090627A/ko not_active Ceased
- 2020-11-13 DK DK24150973.6T patent/DK4328309T3/da active
- 2020-11-13 EP EP24150973.6A patent/EP4328309B1/en active Active
- 2020-11-13 JP JP2021556193A patent/JP7389134B2/ja active Active
- 2020-11-13 ES ES24150973T patent/ES3036322T3/es active Active
- 2020-11-13 CN CN202311355815.7A patent/CN117417265B/zh active Active
- 2020-11-13 KR KR1020227016279A patent/KR20220082885A/ko not_active Ceased
- 2020-11-13 PL PL24150973.6T patent/PL4328309T3/pl unknown
- 2020-11-13 WO PCT/JP2020/042513 patent/WO2021095876A1/ja not_active Ceased
- 2020-11-13 FI FIEP24150973.6T patent/FI4328309T3/fi active
- 2020-11-13 CN CN202080079111.XA patent/CN114728016B/zh active Active
- 2020-11-13 CA CA3158293A patent/CA3158293C/en active Active
- 2020-11-13 KR KR1020257012513A patent/KR20250057122A/ko active Pending
-
2022
- 2022-05-13 US US17/743,584 patent/US20220273817A1/en active Pending
-
2023
- 2023-06-08 JP JP2023094459A patent/JP7566078B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN114728016A (zh) | 2022-07-08 |
| ES3036322T3 (en) | 2025-09-17 |
| FI4328309T3 (fi) | 2025-09-09 |
| JP7389134B2 (ja) | 2023-11-29 |
| US20220273817A1 (en) | 2022-09-01 |
| KR20220082885A (ko) | 2022-06-17 |
| JPWO2021095876A1 (https=) | 2021-05-20 |
| PL4328309T3 (pl) | 2025-11-17 |
| EP4059505A4 (en) | 2023-01-11 |
| WO2021095876A1 (ja) | 2021-05-20 |
| CN117417265A (zh) | 2024-01-19 |
| KR20250171478A (ko) | 2025-12-08 |
| CA3158293C (en) | 2024-06-25 |
| EP4328309A2 (en) | 2024-02-28 |
| EP4059505B1 (en) | 2024-02-21 |
| EP4328309B1 (en) | 2025-07-02 |
| KR20250057122A (ko) | 2025-04-28 |
| EP4059505A1 (en) | 2022-09-21 |
| KR20240090627A (ko) | 2024-06-21 |
| CN114728016B (zh) | 2024-10-29 |
| CN117417265B (zh) | 2026-02-10 |
| EP4328309A3 (en) | 2024-09-25 |
| JP7566078B2 (ja) | 2024-10-11 |
| CA3158293A1 (en) | 2021-05-20 |
| JP2023116626A (ja) | 2023-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4328309T3 (da) | Lipidsammensætning | |
| EP3981435A4 (en) | FAT COMPOSITION | |
| DK3924443T3 (da) | Compositions | |
| EP3853332C0 (en) | COMPOSITION | |
| EP3882323A4 (en) | COMPOSITION | |
| EP3930851A4 (en) | COMBINATION THERAPIES | |
| EP3919491C0 (en) | AKT INHIBITOR | |
| SI3927315T1 (sl) | Okusne formulacije | |
| EP3871694A4 (en) | COMPOSITION | |
| DK3840596T3 (da) | Sammensætning | |
| EP3742771C0 (en) | M2M SM-SR TO SM-DP NOTIFICATION | |
| EP3981256A4 (en) | COMPOSITION | |
| EP3941942A4 (en) | COMPOSITION | |
| EP3897866C0 (en) | ANTIMICROBIAL COMPOSITION | |
| EP4049824C0 (en) | MOLD | |
| EP3954721A4 (en) | Composition | |
| EP3999039A4 (en) | PRETOMANID COMPOSITIONS | |
| EP3914303C0 (en) | VIRUCIDAL COMPOSITION | |
| DK3908321T3 (da) | Farmaceutisk sammensætning | |
| EP3741814C0 (en) | COMPOSITION | |
| PT3765379T (pt) | Composições | |
| DK3911298T3 (da) | Formuleringer | |
| DK3738452T3 (da) | Fordamper | |
| EP3805997A4 (en) | LIPIDNANOTABLET | |
| EP3829532A4 (en) | KERATIN COMPOSITIONS |